Introduction: GlaxoSmithKline is the United Kingdom based
leading, global, research-based healthcare and pharmaceutical company. In India,
it is the Number One Pharmaceutical Company with a market share of 7.0 per cent.
GSK commands the number one position in six of the 10 therapeutic categories in
which it operates. Other than pharmaceuticals, GSK has two businesses - Agrivet
Farm Care (AFC) and Qualigens Fine Chemicals (QFC).AFC is the market leader in
the animal health sector with an estimated market share of 10 per cent. It has
a significant presence in the cattle segment and also markets a range of specialized
poultry products. QFC has an estimated market share of 29 per cent in the laboratory
chemicals market. It also has a significant presence in the Diagnostics business.
GSK has four manufacturing units in India, located at Thane, Nashik, Mysore and
Bangalore. The 2000 -strong field force of GSK, backed by a nation wide network
of over 4000 stockists, ensures that the company’s products are readily
available across the nation. This combined with the quality of the products means
that GSK is able to strengthen the hands of doctors by offering superior treatment
and healthcare solutions. It is the company constant endeavor to improve the quality
of life by enabling people to do more, feel better and live longer.
The
main objective of this study is to understand and examine the impact
of merger between Glaxo Wellcome and Smithkline Beecham on Indian pharmaceutical
industries. That merger happened in 2000 between Glaxo and Smithkline in UK. The
Merged Company has its operations in India, so the author wants to know about
the implications for GlaxoSmithKline of their operations in India.
'One plus one makes three' This is the special alchemy of Merger and
Acquisitions. When two firms, often about the same size, agree to go forward as
a new single company rather than remain separately owned and operated, a merger
happens. Mergers facilitate synergies between the merged companies, generate efficiency,
competitiveness, and increase the economies of scale, spreading costs, acquiring
new technology over a large customer base. By this Research paper I have attempted
implications of the successful merger from July 05, 2000 till date in Glaxo Wellcome
with Smith Kline Beecham. GlaxoSmithKline plc is a leading research-based pharmaceutical
company of the world, has had a presence in India since 1924, and is a leading
pharmaceutical company in the country today, employing more than 4,000 people.
GSK India is organized into three business segment: Pharmaceuticals the predominant
business, Agrivet Farm care and Qualigens Fine Chemicals. In this Research paper,
it is discussed on the merger between Glaxo Wellcome and SmithKline Beecham pharmaceutical
company. As international business activities discussed on reasons behind merger,
benefits of merger and in the context of Indian market what are the implications
of GlaxoSmithKline Pharma Company in Research and Development, product Development
and Key success factor in Indian market that provides knowledge of market nature.
We will try to give the clear view of the business activities of GlaxoSmithKline
Company which is UK based, in context of mainly Indian market as well as worldwide
in this Research report.
Number of Pages of Project Report: 107
Package Includes: Synopsis/Project Proposal + Project Report
Project Format: Document (.doc)
Table of Contents of Project Report:
Part I –Introduction
Research Objective and justifications
Report Outline
Part-II Industry Description
GSK-The Big Picture
Factors for success in India
References
Part-III Literature review
Chapter One –Merger: An Introduction
1.1 Introduction
1.2 The Main Idea
1.3 Types of Merger
1.4 Reasons for International M&A
Chapter Summary
References
Chapter Two-Nature of Indian pharmaceutical
Industry
2.1 Introduction
2.2 Nature of Indian Pharmaceutical Industry
2.2.1 Industry Scenario
2.2.2 Market Scenario ((Projected Pharmaceutical Market, 2004-2009))
2.2.3 New Product Launches underlie market growth
2.2.5 Key Opportunities
2.2.6 FDI in Indian pharma
2.2.7 Strategy and Trends
2.2.8 Research and Development
2.2.9 SWOT Analysis
2.2.10 Mergers and Acquisitions in Pharma
2.2.11 Good Opportunities for ‘big pharma’
References
Chapter Three-Merger between Glaxo Wellcome
Smithkline Beecham
3.1 Introduction
3.2 Merger rationale
3.2.1 Rapid advances in Science and Technology
3.2.2 The growing importance of marketing power
3.2.3 The emergence of patients as consumers
3.3 Merger Benefits
3.3.1 Short term growth
3.3.2 Medium term growth
3.3.3 Long term growth
3.4 Business performance of GSK
Chapter summary
References
Chapter Four-Research Methodology
4.1 Introduction
4.2 Primary Research
4.3 Secondary Research
4.4 Sources of Information
4.5 Research design
4.6 Qualitative research
4.7 Exploratory research
4.8 Data Collection Technique
4.8.1 Primary Data
4.8.2 Exploratory Research Design Secondary Data
4.8.3 Computerized Database
4.8.4 The Interview
4.9 Limitations of study
References
Chapter Five –Factors that support the research
Objectives
5.1 Introduction
5.2 Foreign Direct Investment
5.2.1 Forms of FDI
Chapter Summary
Chapter Six-Research Findings
6.1 Introduction
6.2 About R&D of GlaxoSmithKline
6.2.1 Research Design
6.2.2 Discovering new medicines
6.2.3 Genetic Research
6.2.4 Discovery Research
6.2.5 Drug Discovery
6.2.6 Pre-Clinical Development
6.2.7 Global Commercial Strategy
6.2.8 Clinical Trails
6.2.9 Collaboration and Partnership
6.2.10 Big Pharma to launch patent protected products in India
6.2.11 Technology, Absorption, Adaptions and Innovation
6.2.12 R&D centers in India
6.2.13 Expenditure on R&D
6.3 Product making- By GSK
6.3.1 Collaboration with Galapagos
6.3.2 Collaboration with Path
6.3.3 Collaboration with IAVI
6.3.4 H5NI avian flu Strain
6.3.5 For HIV/AIDS
6.3.6 Vaccine launchers
6.3.7 Pharmaceutical Products (Progress in 2009)
6.3.8 Available products in India
6.4 Marketing strategy of GlaxoSmithKline
Chapter Summary
References
Chapter Seven – Discussion & Analysis
7.1 Introduction
7.2 Merger-Boom or Bane
7.3 Analysis//Summary
7.3.1 Rationale
7.3.2 Schemes of arrangement
7.3.3 Results of the implementation of Merger
7.3.4 Foreign exchange earnings and outgo of GlaxoSmithKline
Conclusion
Bibliography
Appendices
Annexure A-Questionnaire
Annexure B-Corporate Images
